CardioGen-82 is a radionuclide generator that produces Rb-82 chloride injection; the Rb-82 emits the radiation detected in a PET scan.
Rb-82 is a medical isotope with a short half-life (75 seconds), and is derived from strontium-82 (Sr-82), which has a half-life of 25 days.
Rb-82 is collected from the generator column by injecting a solution of normal saline through the column. Under normal conditions, only the Rb-82 is released into the solution, while the strontium remains attached to the column.
To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this apge.
FDA Drug Safety Communication: Planned return of CardioGen-82 to market with new Boxed Warning
FDA Drug Safety Communication: Update: Preliminary findings from ongoing investigations of CardioGen-82[ARCHIVED]
FDA Drug Safety Communication: FDA alerts healthcare professionals to stop performing heart scans with CardioGen-82 due to potential for increased radiation exposure in patients[ARCHIVED]
FDA Drug Safety Communication: Increased radiation exposure due to undetected strontium breakthrough when using CardioGen-82 for cardiac positron emission tomography (PET) scans[ARCHIVED]